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Background: In an earlier study we demonstrated the feasibility to create tissue engineered venous scaffolds
in vitro and in vivo. In this study we investigated the use of tissue engineered constructs for ureteral replacement in
a long term orthotopic minipig model. In many different projects well functional ureretal tissue was established
using tissue engineering in animals with short-time follow up (12 weeks). Therefore urothelial cells were harvested
from the bladder, cultured, expanded in vitro, labelled with fluorescence and seeded onto the autologous veins,
which were harvested from animals during a second surgery. Three days after cell seeding the right ureter was
replaced with the cell-seeded matrices in six animals, while further 6 animals received an unseeded vein for ureteral
replacement. The animals were sacrificed 12, 24, and 48 weeks after implantation. Gross examination, intravenous
pyelogram (IVP), H&E staining, Trichrome Masson’s Staining, and immunohistochemistry with pancytokeratin
AE1/AE3, smooth muscle alpha actin, and von Willebrand factor were performed in retrieved specimens.
Results: The IVP and gross examination demonstrated that no animals with tissue engineered ureters and all
animals of the control group presented with hydronephrosis after 12 weeks. In the 24-week group, one tissue
engineered and one unseeded vein revealed hydronephrosis. After 48 weeks all tissue engineered animals and
none of the control group showed hydronephrosis on the treated side. Histochemistry and immunohistochemistry
revealed a multilayer of urothelial cells attached to the seeded venous grafts.
Conclusions: Venous grafts may be a potential source for ureteral reconstruction. The results of so far published
ureteral tissue engineering projects reveal data up to 12 weeks after implantation. Even if the animal numbers of
this study are small, there is an increasing rate of hydronephrosis revealing failure of ureteral tissue engineering
with autologous matrices in time points longer than 3 months after implantation. Further investigations have to
prove adequate clinical outcome and appropriate functional long-term results.
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While there are many operative techniques to recon-
struct the urethra, strictures and injuries of the ureter
remain a challenging problem [1]. The extent of surgical
treatment depends on the length and localization of the
stricture. Especially long defects require extensive sur-
gery [1]. In patients with long strictures in the lumbar* Correspondence: georg.bartsch@kgu.de
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unless otherwise stated.ureteral segment, bowel segments have to be applied to
reconstitute urine drainage. The search for an ideal re-
constructive technique is still ongoing. We hypothesized
that the use of tissue engineered venous scaffolds is a
potential way to reconstruct ureteral defects [2].
We have previously shown that tissue engineered ven-
ous patches survived in a small animal model and deter-
mined that porcine urothelial cells adhere to fresh venous
matrices from the porcine inferior vena cava [2]. Further-
more, we demonstrated that these tissue engineered con-
structs survived in vivo, revealing adequate vasculaturetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Still, these tissue engineered constructs were not exposed
to urine. Most other published data on orthotopic ureteral
reconstruction have performed studies with limited follow
up (up to 12 weeks) [3-12]. For reconstruction purposes
long time durability is of major importance.
In this study we investigated the potential use of tissue
engineered autologous veins for ureteral reconstruction
in an orthotopic porcine model with long-term follow




Figure 1 Photodocumentation and evaluation of the urologic tract. (a
vein transplant after 12 weeks. (c) tissue engineered ureter after 48 weeks.engineered vein transplants are a feasible source for per-
manent ureter substitution.
Results
Macroscopic evaluation of organs and IVP
Photo documentation and evaluation of the urinary
upper tract (Additional file 1: Table S1) revealed that
none of the animals showed any severe signs of hydrone-
phrosis after 12 weeks (Figure 1 a,b). After 24 weeks one
animal with an unseeded venous construct and one with) tissue engineered ureter after 12 weeks. (b) ureter with unseeded



















Figure 3 Average shortening of the ureteral patch (in cm) after
12, 24, and 48 weeks (tissue engineered vs. control). The
average shortening of the length of the graft was higher in the
animals with unseeded grafts when compared to tissue engineered
scaffolds (1.7 cm versus 1.0 cm).
(a) (b)
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phrosis. After 48 weeks all tissue engineered animals
and none of the control group revealed hydronephrosis
(Figure 1 c,d). During the explantation of the urological
tract a mild scar formation was evident in the retroperi-
toneal space of all animals. No calcifications and no
stone formation were detected. There was no significant
difference in scar formation between the seeded and un-
seeded animals. The established scoring system showed
a slight advantage for tissue engineered venous con-
structs after 12 and 24 weeks. After 48 weeks the ani-
mals of the control group revealed superior results
compared to the animals with tissue engineered con-
structs (Figure 2).
The average implanted venous length at time of sur-
gery was 3.0 cm in tissue engineered animals and 3.3 cm
in control group. The average difference in length of the
constructs 48 months after surgery compared to time of
implantation was 1.5 cm in the tissue engineered - and
2.25 cm in the unseeded group (Figure 3).
The performed IVPs revealed similar results compared
to the gross examination. None of the animals of the 12-
week time point (tissue engineered or control group)
presented with hydronephrosis. At 24 weeks one tissue
engineered and one animal with unseeded construct re-
vealed hydronephrosis (Figure 4). After 48 weeks all tis-
sue engineered animals and none of the control group
showed a significant hydronephrosis on IVP.
Histological and immunohistological analyses
Fluorescently labeled (PKH26) autologous urothelial cells
seeded onto the veins were easily identified within the tis-
sue engineered scaffolds (Figure 5). No fluorescence was
noticeable in unseeded scaffolds (data not shown).
H&E staining revealed an epithelial like looking cell layer
in all animals with tissue engineered constructs, while un-
seeded scaffolds did not reveal an urothelial cell layer. No

















P = 0.10n.s. n.s.
Figure 2 Average hydronephrosis score, including kidney size,
parenchyma thickness, renal pelvis and the ureter size
proximal to the implanted construct after 12, 24, and 48 weeks
(tissue engineered vs. control).was evident in all implanted scaffolds (Figure 6a). In the
Trichrom-Masson staining the venous scaffolds did not
show major histological changes (representing scar tissue
formation) over the time course of 48 weeks (Figure 6b).
Immunohistochemical workup staining for Pancyto-
keratin AE/AE3 proved the evidence of an urothelial cell
layer on top of the tissue engineered matrices and on
native ureteral tissue. The unseeded scaffolds did not re-
veal urothelial cells on the veins during the 48 weeks
(Figure 7a).
Smooth muscle α-Actin staining revealed a well-
developed muscular layer in the native ureters from
contralateral untreated side, while no smooth muscle α-
Actin was evident in venous segments (Figure 7b).
Factor VIII staining showed well-vascularized tissue in
native ureteral tissue, as well as in tissue engineered and
unseeded scaffolds (Figure 7c).Figure 4 IVP 24 weeks after surgery. (a) The arrow shows free transit
of the contrast medium thru the interposed segment with the tissue
engineered venous graft. (b) ureteral construction with unseeded
scaffolds. The arrow shows delayed excretion of contrast material.
Figure 5 Staining of PKH26 labeled urothelial cells on the mucosal layer of the implanted scaffolds after 24 weeks.
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No major differences in urea and creatinine levels were
detected in the serum analysis after 12 and 24 weeks
in vivo. Still after 48 weeks a distinct elevation of cre-
atinine was evident in the tissue engineered animals







Figure 6 Histochemistry in vivo with (a) H&E and (b) Trichrom-Masson s
Middle: ureter construction with unseeded scaffolds. Right side: native ureter.
of the venous scaffold (V) (left row) while in the unseeded grafts no urothelial
architecture with urothelium (U), submucosal layer (SM), and muscular layer (M
in the Trichrom-Masson staining the low content of collagen (blue color) in aurea in the hydronephrotic animals is explainable with a
healthy contralateral kidney.
Discussion
Many studies have been published on ureteral recon-







taining after 48 weeks (50x), Left side: tissue engineered ureter.
In the tissue engineered ureter an urothelial lining (U) is evident on top
lining is noticeable. In the third row the typical ureteral histologic
) is recognisable. While the H&E staining reveals the general architecture,




Figure 7 Immunohistochemistry in vivo after 48 weeks. Left column: native ureter, middle column: tissue engineered ureter, right column:
unseeded transplants (a) Panytokeratin AE1/AE3 (200x). (b) Smooth Muscle Actin (50x). (c) Von Willebrand Factor (50x). Specific Immunostained
cells were clearly distinguiable from immunoreactivity of investigated tissue.
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submucosa [6,7], dura [8], and peritoneum [9] have been
investigated. Also synthetic materials were evaluated in
animal models [10-12]. Most of these studies were limited
to short-term evaluations up to 12 weeks. Rat models
showed that acellular matrices may be successfully applied
for ureteral reconstruction. In these reconstructed ureters
no smooth muscle regeneration was visible [7]. The lack
of a muscular layer was also evident in our study. The thin
smooth muscle layer within the vein, which was demon-
strated in our previous study in vitro and in vivo [2], was
not detectable. One possible reason for loss of muscle cells
is the 3 days long ischemic interval during the in vitro cell
seeding process. Authors of recent studies concluded that
































Figure 8 Urea and creatinine levels of animals after 24 and 48 weeks
after 48 weeks revealed an increase of the creatinine levels.essential to establish a well working neoureter [2,13-17].
Therefore, the missing muscular layer may be a reason,
why in long-term results of this study we experienced a
high rate of ureteral obstruction. To get a high and fast re-
vascularization of the grafts we transferred all recon-
structed segments into a mold of the psoas muscle that
was formed by removing a muscle fiber. This was per-
formed due to limited access to omentum in a porcine
animal model.
Even if Factor VIII staining revealed well-vascularized
tissues in tissue engineered and control group specimens,
additional treatment of veins with angiogenic factors may
help to avoid the loss of muscular layer, and may therefore
avoid stricture formation. A possible way of neovasculari-





. Only the creatinine levels of animals with tissue engineered grafts
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cells in combination with bone marrow-derived mono-
nuclear cells and noticed well-established angiogenesis in
the combination group [14].
An alternative method to form a muscle layer may be
the additional seeding of autologous smooth muscle
onto the transplants.
Concerning the necessity of a urothelial layer, earlier
studies have determined that short gaps are closed by in-
growing urothelium, but longer distances lack an urothe-
lial lining. Dorin et al. showed that the maximum distance
for tissue regeneration is 0.5 cm [18]. The urothelial layer
is reported to essential to protect the neoureter from ag-
gressive urinary components, which may lead to extensive
scarring and consecutive stenosis. This hypothesis may be
supported with the 100% patency rate in the short-term
(12 weeks). Still, we have to acknowledge that in our study
three out of four tissue engineered constructs failed in the
long term (24 and 48 weeks), while unseeded venous
grafts performed better (only one out of four ureters
failed). For drawing the conclusion that urothelial cell
seeding is not necessary and that the endothelial cells on
the native autologous veins are sufficient to reconstruct
the ureter the sample size of this cohort is too small. The
risk for a surgeon dependent bias of result is low; all con-
tributing surgeons have high experience in reconstructive
urologic procedures.
Data on ureteral reconstruction using venous segments
is sparse. Starting from 1976 venous material was investi-
gated for ureteral and urethral reconstruction in animals.
Klippel and Hohenfellner performed a total substitution of
the ureter using fresh Rhesus monkey and human umbil-
ical cord veins with an overall success rate of 60% [19].
Kjaer et al. examined total replacement of a part of the ca-
nine urethra with venous homografts. They showed a suc-
cess rate of 88.9% [20]. Unfortunately a long time follow
up is missing. The canine urethra was also replaced using
veins by Hubner et al. The mean follow up was 118 days.
18 of 19 dogs showed no problems [21] .
In a small clinical trial of Pompeius and Ekroth, ureteral
replacement with a venous patch was investigated in
humans. Four patients with a ureteral stricture length of at
mean 2 cm underwent ureteral substitution by an autolo-
gous venous patch. After a mean follow up of 6.1 years all
patients had good renal function. Two of four presented
with a mild hydronephrosis in radiographical controls [22].
None of published studies on veins for ureteral recon-
struction showed that endothelial lining was replaced
with urothelial cells.
In this study we were able to demonstrate that urothelial
cells adhere to veins. Our results after 12 weeks were
promising. We did not notice severe signs of hydronephro-
sis in IVPs and macroscopic examination in experimental
and control group. These findings suggested that thismethod may be a feasible method to substitute a ureteral
defect or stenosis. After 24 weeks, the first animal pre-
sented with hydronephrosis in both groups, while we did
not find any differences between tissue engineered vein
transplants and unseeded constructs in the radiographic
and macroscopic examination. The results after 48 weeks
were surprising to us, since all animals with cell-seeded
transplants presented with serious signs of hydronephrosis.
Nevertheless, substitution of the ureter with unseeded au-
tologous veins worked well.
In this study we showed that tissue engineering of
urothelial cells seeded on venous constructs is feasible. In
minipigs with tissue engineered venous graft, an urothelial
multilayer was evident up to 48 weeks. The urothelial cells
on the tissue engineered construct revealed fluorescence,
proofing that seeded urothelial cells survived on the ven-
ous scaffold. Unseeded controls did not show an urothelial
cellular layer, proofing the principle that distances longer
than 0.5 cm cannot be bridged by urothelium growing into
the scaffold from native and healthy ends. It is so far not
explainable why the ureteral segment without urothelial
cell lining performed better than these with seeded cells.
Conclusions
Tissue engineered venous grafts are a potential source to
reconstruct ureteral tissue, but are currently not ready for
clinical implementation. Although all implants showed
good patency after 12 weeks, long-term outcomes were in-
sufficient and showed high rates of hydronephrosis particu-
larly in tissue engineered animal group. Future modified
studies on tissue engineered venous matrices for urogenital
reconstruction will show, whether this method will be
transferable to clinical trials.
Materials and methods
Retrieval of bladder mucosa
All animal procedures were performed in female minipigs. All
procedures were approved by the State Animal Committee,
Reutlingen, Baden Wuerttemberg, Germany. Porcine uro-
thelial mucosa was harvested from six Goettingen Minipigs
using a small laparatomy. General anesthesia was initiated
with Propofol 2 mg/kg intraveneously and maintained with
oxygen/isoflurane. The minipigs were placed into a supine
position, washed and prepped. A median skin incision was
performed in the lower abdomen. The detrusor muscle
was split, the mucosal layer was exposed and a one cm2
large piece of mucosal tissue was excised. Six animals
served as controls and did not undergo surgery for urothe-
lial mucosa harvesting.
Cell preparation and culture
The autologous urothelial cells were isolated and expanded
according to the protocol described by Oberpenning et al.




Figure 9 Havest of a jugular vein and using it for reconstruction of
the ureter. (a) Harvest of a jugular vein from the minipig’s neck. (b) Free
jugular vein opened longitudinally with endothelial side up. (c) Ureteral
reconstruction and measuring the length of the tissue engineered
venous scaffold.
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(K-SFM) supplemented with bovine pituary extract, EGF
5 ng/ml (GIBCO/BRL), and 1% antibiotics (GIBCO/BRL).
Fluorescence labeling the primary urothelial cultures
All primary urothelial cell cultures were labeled with
PKH26 fluorescence dye (Sigma, Austria) according to the
manufacturer’s instruction. After organ retrieval a small
specimen from the neoureter was excised for frozen sec-
tions. The native slides were investigated by fluorescence
microscopy [excitation (551 nm) and emission (567 nm)].
Harvest of porcine veins
Fresh autologous porcine jugular veins were harvested in
a second procedure three weeks after the first surgery. For
this procedure all 12 minipigs were incised on the right
side of their necks (Figure 9a). A full length of 4 cm of the
vein was excised. The vein was opened longitudinally and
marked which a suture on the endothelial side to distin-
guish this side easily from the serosa-side (Figure 9b). The
veins were used in a native fashion and were not processed
chemically or enzymatically.
Seeding the venous grafts
Six venous grafts were placed into silicone molds, and
were seeded with autologous urothelial cells, cultured
and expanded in vitro at a seeding concentration of
25×106 cells/ml. The resuspended cells were transferred
onto the venous grafts in a volume of 100 μl. Medium
was changed every 24 hours. After three days in vitro
the seeded veins were implanted into the corresponding
animals. Unseeded veins have been incubated with the
same medium for the same time period.
Orthotopic ureteral reconstruction
The right ureter and kidney were exposed transperitoneally
using a median laparotomy. The ureter was incised and
the ventral ureteral wall was excised over a length of 3 cm,
leaving only a 2 mm wide rim of the posterior ureter in
place. The vein transplants were sutured as an onlay patch
to the remaining rim of ureter (Figure 9c). A five French
ureteral stent was placed. The proximal end of the stent
was closed and placed subcutaneously to be removed after
six weeks. The vein transplants were marked with two pro-
lene sutures at its ends, to be easily recognizable at time of
autopsy. Antibiotics were administered for five days after
surgery. For postoperative pain management all animals
received Carprofen 4 mg/kg for five days, twice a day.
Follow up
12, 24 and 48 weeks after ureteral reconstruction four
animals (two tissue engineered and two control animals)
at each time were examined under general anesthesia
and subsequently sacrificed.Intravenous pyelogram
An intravenous pyelogram (IVP) was performed in every
animal prior to organ retrieval. All animals were injected
1 ml contrast medium per kg of body weight. The excretion
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tion using 60–70 kV und 20–25 mA.Serum creatinine and urea
Serum creatinine and urea levels were determined accord-
ing to the guidelines of the Institute of Clinical Chemistry,
University of Ulm.Macroscopic evaluation of urinary tract
During autopsy, kidneys, ureters, bladder, and the urethra
were excised in one piece. All organs were photo-
documented. For an objective evaluation of the urological
tract a scoring system was established.
The score includes the size of kidneys, parenchyma
thickness, grade of dilation and the dilation of the ureter
proximal to the area of reconstruction (Additional file 2:
Table S2).
The site of reconstruction was identified by the two
prolene marking sutures. The distance between sutures
was measured and finally excised for further analyses.
Ratio between intraoperative length and length after sac-
rificing was determined for each animal. A correspond-
ing area was also excised from the left untreated ureter
as a control. One part of tissue was used for histochem-
istry and immunohistochemistry, another part to detect
the fluorescent labeled cells seeded onto the veins.Histochemical analyses
The retrieved venous specimens were fixed in 10% for-
maldehyde. Sections were stained with hematoxilin and
eosin (H&E). Furthermore, a Masson’s Trichrome (MT)
staining was performed to investigate potential changes
within the connective tissue of the venous matrices.Immunohistochemistry
Paraffin embedded 5 μm sections were stained for pancyto-
keratin AE1/AE3, smooth muscle α-actin, and Factor VIII
(all from DAKO). Standard avidin-biotin complex immuno-
histochemistry was used. The slides were incubated sequen-
tially with primary antibody (1:100, anti-pancytokeratin
AE1/AE3, anti-SM-α-actin, anti-Factor VIII), biotinylated
secondary antibody, avidin-biotin complex, and chromo-
genic substrate 3.3′-diaminobenzidine. Slides were evalu-
ated for adequacy using a standard bright field microscope.Statistical analyses
For statistical analyses two-tailed, unpaired Student’s T-test
and Mann-Whithney U-test were performed where applic-
able. Level of significance was set to P <0.05.
Graphs were plotted with Mean + SE. Statistical Analyses
and graphs were performed using GraphPad Prism 5
(La Jolla, CA, USA).Additional files
Additional file 1: Table S1. Descriptive characteristics of 12 minipigs
treated with tissue engineered (TE) autologous venous transplants or
unseeded veins (C) for ureteral reconstruction.
Additional file 2: Table S2. Scoring system for evaluating the gross
examination of the retrieved urinary tract.
Abbreviation
IVP: Intravenous pyelogram; SIS: Small intestine submucosa; TE: Minipig with
Tissue engineered venous transplant; C: Minipig with unseeded venous
transplant for control.
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